E-prostanoid 2 receptor signaling suppresses lung innate immunity against Streptococcus pneumoniae.

Prostaglandins & Other Lipid Mediators
David M AronoffPeter Mancuso

Abstract

Pneumonia is a major global health problem. Prostaglandin (PG) E(2) is an immunomodulatory lipid with anti-inflammatory, immunosuppressive, and pro-resolving actions. Data suggest that the E-prostanoid (EP) 2 receptor mediates immunomodulatory effects of PGE(2), but the extent to which this occurs in Streptococcus pneumoniae infection is unknown. Intratracheal lung infection of C57BL/6 mice possessing (EP2(+/+)) or lacking (EP2(-/-)) the EP2 receptor was performed, as were in vitro studies of alveolar macrophage (AM) host defense functions. Bacterial clearance and survival were significantly improved in vivo in EP2(-/-) mice and it correlated with greater neutrophilic inflammation and higher lung IL-12 levels. Upon ex vivo challenge with pneumococcus, EP2(-/-)cells expressed greater amounts of TNF-α and MIP-2 than did EP2(+/+) AMs, and had improved phagocytosis, intracellular killing, and reactive oxygen intermediate generation. These data suggest that PGE(2)-EP2 signaling may provide a novel pharmacological target for treating pneumococcal pneumonia in combination with antimicrobials.

References

Feb 1, 1989·The Journal of Infectious Diseases·D O SordelliR P Meiss
Mar 1, 1987·American Journal of Obstetrics and Gynecology·P R BennettM G Elder
Sep 3, 1985·Journal of Immunological Methods·R Peck
Jul 10, 2001·The Journal of Infectious Diseases·F DallaireM G Bergeron
Oct 7, 2003·Cellular Immunology·Evros VassiliouDoina Ganea
Mar 24, 2004·Trends in Immunology·Aras Kadioglu, Peter W Andrew
Nov 22, 2005·Microbes and Infection·Wei LiuKathleen A Kelly
May 6, 2006·American Journal of Respiratory Cell and Molecular Biology·Mohamed S ArredouaniLester Kobzik
Feb 3, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Charles N SerhanJohn L Wallace
Feb 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN American Thoracic Society
Aug 4, 2007·Clinical and Experimental Immunology·G Y ParkJ W Christman
Dec 14, 2007·Experimental Lung Research·Helen M Marriott, David H Dockrell
Mar 24, 2009·Clinical and Experimental Immunology·M Si-TaharM Chignard
Apr 9, 2010·Current Opinion in Pulmonary Medicine·Joseph P Lynch, George G Zhanel
Jul 14, 2010·TheScientificWorldJournal·Troy Carlo, Bruce D Levy
Jan 11, 2011·American Journal of Respiratory Cell and Molecular Biology·Lynnelle A PittetJoseph P Mizgerd
Feb 9, 2011·Journal of Theoretical Biology·Amber M SmithFrederick R Adler
Jun 17, 2011·International Journal of Clinical Practice·J A Bosso, R H Drew
Aug 10, 2011·Laboratory animal research·Dong-Gu JeongYang-Kyu Choi

❮ Previous
Next ❯

Citations

Jun 25, 2013·The Journal of Pathology·James N FullertonDerek W Gilroy
Mar 23, 2018·American Journal of Physiology. Lung Cellular and Molecular Physiology·Peter MancusoMartin G Myers
Aug 8, 2018·American Journal of Reproductive Immunology : AJRI·Lisa M RogersDavid M Aronoff
Apr 10, 2016·American Journal of Physiology. Lung Cellular and Molecular Physiology·Jennifer M DolanPeter Mancuso
Jan 18, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Elyara M SoaresDavid M Aronoff
Sep 11, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Zhihong YuanRuxana T Sadikot
May 18, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jennifer M SpethMarc Peters-Golden
Nov 3, 2016·American Journal of Physiology. Lung Cellular and Molecular Physiology·Shannon H LacyRichard P Phipps
Aug 21, 2020·Life Science Alliance·Loka R PenkeMarc Peters-Golden
Aug 6, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Katie L MasonDavid M Aronoff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

The Journal of Immunology : Official Journal of the American Association of Immunologists
David M AronoffPeter Mancuso
American Journal of Respiratory Cell and Molecular Biology
Carlos H SerezaniMarc Peters-Golden
© 2021 Meta ULC. All rights reserved